Swisher SG, Winter KA, Komaki RU, Ajani JA, Wu TT, Hofstetter WL, et al. A phase II study of a paclitaxel-based chemoradiation regimen with selective surgical salvage for resectable locoregionally advanced esophageal cancer: initial reporting of RTOG 0246. Int J Radiat Oncol Biol Phys. 2012;82(5):1967–72.

Article  CAS  PubMed  Google Scholar 

Lordick F, Mariette C, Haustermans K, Obermannova R, Arnold D, Committee EG. Oesophageal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v50–7.

Article  CAS  PubMed  Google Scholar 

Sun JM, Shen L, Shah MA, Enzinger P, Adenis A, Doi T, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398(10302):759–71.

Article  CAS  PubMed  Google Scholar 

Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med. 2021;384(13):1191–203.

Article  CAS  PubMed  Google Scholar 

Secrier M, Li X, de Silva N, Eldridge MD, Contino G, Bornschein J, et al. Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance. Nat Genet. 2016;48(10):1131–41.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Murugaesu N, Wilson GA, Birkbak NJ, Watkins T, McGranahan N, Kumar S, et al. Tracking the genomic evolution of esophageal adenocarcinoma through neoadjuvant chemotherapy. Cancer Discov. 2015;5(8):821–31.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Findlay JM, Castro-Giner F, Makino S, Rayner E, Kartsonaki C, Cross W, et al. Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy. Nat Commun. 2016;7:11111.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dulak AM, Stojanov P, Peng S, Lawrence MS, Fox C, Stewart C, et al. Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet. 2013;45(5):478–86.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Frankell AM, Jammula S, Li X, Contino G, Killcoyne S, Abbas S, et al. The landscape of selection in 551 esophageal adenocarcinomas defines genomic biomarkers for the clinic. Nat Genet. 2019;51(3):506–16.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Noorani A, Bornschein J, Lynch AG, Secrier M, Achilleos A, Eldridge M, et al. A comparative analysis of whole genome sequencing of esophageal adenocarcinoma pre- and post-chemotherapy. Genome Res. 2017;27(6):902–12.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nones K, Waddell N, Wayte N, Patch AM, Bailey P, Newell F, et al. Genomic catastrophes frequently arise in esophageal adenocarcinoma and drive tumorigenesis. Nat Commun. 2014;5:5224.

Article  CAS  PubMed  Google Scholar 

Newell F, Patel K, Gartside M, Krause L, Brosda S, Aoude LG, et al. Complex structural rearrangements are present in high-grade dysplastic Barrett’s oesophagus samples. BMC Med Genomics. 2019;12(1):31.

Article  PubMed  PubMed Central  Google Scholar 

Ramon YCS, Sese M, Capdevila C, Aasen T, De Mattos-Arruda L, Diaz-Cano SJ, et al. Clinical implications of intratumor heterogeneity: challenges and opportunities. J Mol Med (Berl). 2020;98(2):161–77.

Article  Google Scholar 

McGranahan N, Swanton C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell. 2017;168(4):613–28.

Article  CAS  PubMed  Google Scholar 

Saunders NA, Simpson F, Thompson EW, Hill MM, Endo-Munoz L, Leggatt G, et al. Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives. EMBO Mol Med. 2012;4(8):675–84.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Frankell AM, Dietzen M, Al Bakir M, Lim EL, Karasaki T, Ward S, et al. The evolution of lung cancer and impact of subclonal selection in TRACERx. Nature. 2023;616(7957):525–33.

Article  CAS  PubMed  PubMed Central  Google Scholar 

McDonald KA, Kawaguchi T, Qi Q, Peng X, Asaoka M, Young J, et al. Tumor heterogeneity correlates with less immune response and worse survival in breast cancer patients. Ann Surg Oncol. 2019;26(7):2191–9.

Article  PubMed  PubMed Central  Google Scholar 

Morris LG, Riaz N, Desrichard A, Senbabaoglu Y, Hakimi AA, Makarov V, et al. Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival. Oncotarget. 2016;7(9):10051–63.

Article  PubMed  PubMed Central  Google Scholar 

Lopez-Carrasco A, Berbegall AP, Martin-Vano S, Blanquer-Maceiras M, Castel V, Navarro S, Noguera R. Intra-tumour genetic heterogeneity and prognosis in high-risk neuroblastoma. Cancers. 2021;13(20):5173.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ross-Innes CS, Becq J, Warren A, Cheetham RK, Northen H, O’Donovan M, et al. Whole-genome sequencing provides new insights into the clonal architecture of Barrett’s esophagus and esophageal adenocarcinoma. Nat Genet. 2015;47(9):1038–46.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Martinez P, Timmer MR, Lau CT, Calpe S, Sancho-Serra Mdel C, Straub D, et al. Dynamic clonal equilibrium and predetermined cancer risk in Barrett’s oesophagus. Nat Commun. 2016;7:12158.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lonie JM, Barbour AP, Dolcetti R. Understanding the immuno-biology of oesophageal adenocarcinoma: towards improved therapeutic approaches. Cancer Treat Rev. 2021;98:102219.

Article  CAS  PubMed  Google Scholar 

Abbosh C, Frankell AM, Harrison T, Kisistok J, Garnett A, Johnson L, et al. Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA. Nature. 2023;616(7957):553–62.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Al Bakir M, Huebner A, Martinez-Ruiz C, Grigoriadis K, Watkins TBK, Pich O, et al. The evolution of non-small cell lung cancer metastases in TRACERx. Nature. 2023;616(7957):534–42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barbour AP, Walpole ET, Mai GT, Barnes EH, Watson DI, Ackland SP, et al. Preoperative cisplatin, fluorouracil, and docetaxel with or without radiotherapy after poor early response to cisplatin and fluorouracil for resectable oesophageal adenocarcinoma (AGITG DOCTOR): results from a multicentre, randomised controlled phase II trial. Ann Oncol. 2020;31(2):236–45.

Article  CAS  PubMed  Google Scholar 

Song S, Nones K, Miller D, Harliwong I, Kassahn KS, Pinese M, et al. qpure: a tool to estimate tumor cellularity from genome-wide single-nucleotide polymorphism profiles. PLoS One. 2012;7(9):e45835.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet J. 2011;17(1):10–2.

Article  Google Scholar 

Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. arXiv:13033997v2. 2013.

Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The sequence alignment/map format and SAMtools. Bioinformatics (Oxford, England). 2009;25(16):2078–9.

PubMed  Google Scholar